Sp1275
ADVANCEMENTS IN THE EVALUATION AND TREATMENT OF ESOPHAGEAL DISORDERS
Date
May 19, 2024
Tracks
Related Products
CB1 RECEPTOR LOCALIZATION WITHIN THE AFFERENT SPLANCHNIC NEURONS AND ITS IMPACT ON FEEDING BEHAVIOR AND ENERGY EXPENDITURE
BACKGROUND: Our previous research has showed that increased sympathetic nervous activity and decreased cannabinoid receptor 1 (CB1) were associated with increased energy expenditure and weight loss following Roux-en-Y gastric bypass (RYGB) in mice…
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
RNA SEQUENCING FROM BIOPSIES PERFORMED DURING FOOD ELIMINATION AND REINTRODUCTION IDENTIFIES SIGNATURES INVOLVED IN EARLY RECURRENCE OF EOE
RATIONALE: RNA sequencing studies have previously identified impaired barrier function and the subsequent proinflammatory response as critical to the pathogenies of EoE. However, the investigation into disease initiation is often limited by the inability to capture the disease early…
QUESTION AND ANSWER
This session provides a deeper understanding of how and when to use our current state of the art tools for physiology testing. Audience members will appreciate the nuances of esophageal motility reading, when to order which pH test for reflux symptoms…